2006
Patient willingness to take teriparatide
Fraenkel L, Gulanski B, Wittink D. Patient willingness to take teriparatide. Patient Education And Counseling 2006, 65: 237-244. PMID: 16965888, PMCID: PMC1769517, DOI: 10.1016/j.pec.2006.08.004.Peer-Reviewed Original ResearchMeSH KeywordsAbsorptiometry, PhotonAdministration, OralAgedAged, 80 and overBone Density Conservation AgentsChoice BehaviorConnecticutDrug Administration ScheduleFemaleFractures, BoneHealth Knowledge, Attitudes, PracticeHealth Services Needs and DemandHumansInjections, SubcutaneousMiddle AgedMultivariate AnalysisOsteoporosis, PostmenopausalPatient Acceptance of Health CarePostmenopauseRisk AssessmentSocioeconomic FactorsSurveys and QuestionnairesTeriparatideWomenConceptsDaily subcutaneous injectionsTreatment preferencesSubcutaneous injectionFuture fracturesMost womenAbsolute fracture riskTreatment of osteoporosisNovel treatment approachesConjoint analysis questionnairePostmenopausal womenAdaptive conjoint analysis questionnaireDaily injectionsPoor adherenceEfficacy advantageFracture riskPatients' willingnessClinical studiesAge 71Bone densitometryEffective treatmentNumber of subjectsTreatment approachesT-scoreOlder adultsWomen
2003
Association of Endogenous Sex Hormones and Insulin Resistance among Postmenopausal Women: Results from the Postmenopausal Estrogen/Progestin Intervention Trial
Kalish GM, Barrett-Connor E, Laughlin GA, Gulanski BI. Association of Endogenous Sex Hormones and Insulin Resistance among Postmenopausal Women: Results from the Postmenopausal Estrogen/Progestin Intervention Trial. The Journal Of Clinical Endocrinology & Metabolism 2003, 88: 1646-1652. PMID: 12679451, DOI: 10.1210/jc.2002-021375.Peer-Reviewed Original ResearchMeSH KeywordsAdipose TissueAgedBiological AvailabilityBody CompositionBody ConstitutionBody Mass IndexEstradiolEstrogen Replacement TherapyFemaleGonadal Steroid HormonesHomeostasisHumansInsulin ResistanceLogistic ModelsMiddle AgedPostmenopauseProgestinsSex Hormone-Binding GlobulinTestosteroneVisceraConceptsBody mass indexInsulin resistanceBioavailable testosteroneBioavailable estradiolPostmenopausal womenTotal estradiolMass indexSex hormonesPostmenopausal Estrogen/Progestin Interventions (PEPI) TrialHomeostasis model assessment-IRLower SHBG levelsYounger postmenopausal womenYr of menopauseHomeostasis model assessmentHormone replacement therapyEndogenous sex hormonesModel assessment-IRDose-response fashionCross-sectional associationsLogistic regression analysisSHBG levelsTotal testosteroneVisceral adiposityHighest quartileTotal adiposity
2002
Evidence that the IL-6/IL-6 Soluble Receptor Cytokine System Plays a Role in the Increased Skeletal Sensitivity to PTH in Estrogen-Deficient Women
Masiukiewicz US, Mitnick M, Gulanski BI, Insogna KL. Evidence that the IL-6/IL-6 Soluble Receptor Cytokine System Plays a Role in the Increased Skeletal Sensitivity to PTH in Estrogen-Deficient Women. The Journal Of Clinical Endocrinology & Metabolism 2002, 87: 2892-2898. PMID: 12050269, DOI: 10.1210/jcem.87.6.8577.Peer-Reviewed Original ResearchConceptsEstrogen-deficient womenIL-6/ILSkeletal sensitivityIL-6IL-6sREstrogen deficiencyCytokine systemIL-6 soluble receptorUrine N-telopeptideAction of PTHPrevious animal studiesNTx excretionPTH infusionPostmenopausal womenSerum calciumN-telopeptideCytokine productionTNF-alphaExaggerated increaseIL-1betaHormonal statusBaseline valuesSoluble receptorAnimal studiesColony-stimulating factor-1